The presence NTRK gene fusions is one of the eligibility requirements for the recently FDA-approved therapy Vitrakvi (larotrectinib), a therapy indicated in adult and pediatric patients with solid tumors regardless of the type of tumor. NTRK gene fusions have been described in many cancers at various frequencies including common cancers such as lung, thyroid, and colorectal cancers.

Neuro-oncology is a complex field undergoing rapid changes with the advancement and evolution of sophisticated genetic testing. Evidence continues to grow in support of broad molecular and cytogenetic analysis for patients with brain tumors.

Mayo Clinic pathologists, researchers, and a wide spectrum of allied health staff are in National Harbor, Maryland for the 108th United States and Canadian Academy of Pathology Meeting. Visit us at booth #510 to discuss how our testing can integrate with your practice.

This week’s Research Roundup highlights how the EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis.

This week’s Research Roundup highlights the diagnostic accuracy of echocardiography and intraoperative surgical inspection of the unicuspid aortic valve.

Genetic alterations in low-risk prostate cancer diagnosed by needle biopsy can identify men that harbor higher-risk cancer in their prostate glands, Mayo Clinic has discovered.

Researchers at the Mayo Clinic Center for Individualized Medicine have discovered that large chromosomal rearrangements present in mesothelioma could make it possible to understand which patients are likely respond better to immunotherapy.

AMA PRA Category 1^TM / ABPath MOC
April 15–16, 2019 | Minneapolis, Minnesota
This comprehensive, case-based conference will prepare attendees for both common and uncommon clinical scenarios where molecular testing should be applied in a cost- and time-effective manner.

Robert Jenkins, M.D., Ph.D., a pathologist and cancer geneticist at Mayo Clinic, provides an overview of the new neuro-oncology expanded gene panel and chromosomal microarray testing available through Mayo Medical Laboratories. He discusses which types of patients should be tested, how these tests improves upon previous methods, and what clinical action can be taken from the results of this testing.

This week’s Research Roundup highlights neoantigenic potential of complex chromosomal rearrangements in mesothelioma.

Researchers at Mayo Clinic have identified three specific gene types that account for a known two- to three-fold increase in myeloma diagnoses among African-Americans. Researchers also demonstrated the ability to study race and racial admixture more accurately using DNA analysis. The findings were published today in Blood Cancer Journal.

This week’s Research Roundup highlights carcinoid heart disease in patients with bronchopulmonary carcinoid.

This week’s Research Roundup highlights the risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics.